Home › Funds › DRIEHAUS CAPITAL MANAGEMENT LLC › ARWR

DRIEHAUS CAPITAL MANAGEMENT LLC position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

DRIEHAUS CAPITAL MANAGEMENT LLC reported holding 1,350,556 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$110.1M, representing 0.64% of its reported portfolio and ranking #41 among its reported holdings. DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed ARWR holdings in 6 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.35M sh
Reported value held$110.08M
Portfolio Weight0.64%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DRIEHAUS CAPITAL MANAGEMENT LLC's ARWR position evolved

DRIEHAUS CAPITAL MANAGEMENT LLC first disclosed a stake in ARWR in Q3 2023 at 29,493 shares (US$792K). The position peaked in Q4 2025 at 1,769,340 shares, worth US$117.5M. Across 6 filings, DRIEHAUS CAPITAL MANAGEMENT LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,350,556 shares valued at US$110.1M — an increase of 160,221 shares quarter over quarter.. Notable position changes include a 33% trim in Q1 2026 (shares rose 30% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 29.49K $792.48K New
Q4 2023 29.49K $902.49K Hold
Q3 2025 2.10M $72.41M New
Q4 2025 1.77M $117.47M Reduce
Q1 2026 1.19M $74.63M Reduce
Q2 2026 1.35M $110.08M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 52 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has DRIEHAUS CAPITAL MANAGEMENT LLC held ARWR?

DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed ARWR holdings in 6 of the last 12 reported quarters, going back to Q3 2023.

What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in ARWR?

As of Q2 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 1.35M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $110.08M, representing 0.64% of its reported portfolio and ranking #41.

Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling ARWR?

In the latest 13F filing (Q2 2026), DRIEHAUS CAPITAL MANAGEMENT LLC increased its position in ARWR. The position peaked in Q4 2025 at 1.77M shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.